

PR#: 4346 Deviation No.:D-2020-0230

Record Status: Closed-Done

## 基本信息 General Information

厂区 Division: Innovent Biologics (Su Zhou) Co., Ltd

发起人 Originator: 方, 银川(PID-000082) 发起日期 Date Opened: 2020.08.02

简短描述 Short Description:

M1b DS1 DS2006009批次AC1上样管道未及时排气泡 The sample pipe did not discharge bubbles in time during AC1 of

DS2006009

到期日期 Date Due: 2020.08.04 关闭日期 Date Closed: 2020.08.04

#### 偏差信息 Deviation Information

发现人 Discovery By: 方银川05030032 发现日期 Discovery On: 2020.08.01 汇报人Report By: 方银川05030032 汇报日期 Report On: 2020.08.01 发生部门 Occurred Department: M1b DS1 汇报部门 Report Department: M1b DS1

偏差描述 Deviation Description:

2020.08.01 15:42在除病毒前纯化间(26C15)进行批次DS2006009信迪利单抗注射液M1b 3000L原液纯化 AC1上样时,现场人员(05030032)发现未执行批记录中"1.3.11 产品管道排空冲洗"步骤,与《信迪利单抗注射液M1b 3000L原液纯化批生产记录》(BPR100322)中规定亲和层析上样前上样管道应排空冲洗不符,故发起偏差。

描述的附件 Description attachment:

是否及时上报? Reporting in Time?: Yes

未及时上报的理由 Reason for not in Time:

已采取的即时措施 Immediately Action Taken:

08/02/2020 09:35 PM (GMT+8:00) added by 银川方 (PID-000082):

1.重新执行信迪利单抗注射液M1b 3000L原液 (DS2006009) 纯化批生产记录中 "1.3.11 产品管道排空冲洗" 步骤。 生产部 2020.08.01

即时措施附件 Immediately Action Attachment:

附件1.重新执行1.3.11 产品管道排空冲洗步骤.jpg

厂房设施名称 Facility Name: 产品所属阶段 Product Phase:

M1b Commercial

### 初步影响/风险评估Initial Impact/Risk Assessment

产品影响评估 Product Impact Assessment:

偏差调查:

本次偏差发生时间是2020.08.01 15:42,在信迪利单抗注射液M1b 3000L原液(DS2006009)亲和层析Cycle1上样时,现场人员(05030032)发现未执行《信迪利单抗注射液M1b 3000L原液纯化批生产记录》(BPR100322)中"1.3.11产品管道排空冲洗"步骤,就已经开启IBI308 AC Process程序,为防止因未排空上样管路导致气泡进入层析系统,立即Pause亲和层析程

序。在T0112-CH0301管路打开后,通过观察纯化区域上样管路中的视镜,未发现DS2006009 CF收获液,说明此时产品尚未进入亲和层析系统。立即上报MST、QA和生产,经讨论决定,手动关闭T0112罐底阀门XV-T0112-14,重新执行"1.3.11产品管道排空冲洗"步骤,管路排气泡完成后,继续开始上样。

经调查,未执行的"1.3.11 产品管道排空冲洗"步骤在《信迪利单抗注射液M1b 3000L原液纯化批生产记录》(BPR100322)第21页上,操作人员(05030045和05030032)在执行"1.3.10 亲和层析Cycle1的500L配液袋安装"时,将批记录第20页、21页拿至一次性混合器旁进行确认操作,未及时归还至亲和层析系统处的整份批记录中,也未与后续操作人员(20002046和20000387)进行沟通,因此操作人员(20002046和20000387)在执行批记录第22页"1.3.12 亲和层析Cycle1"步骤时由于批记录第21页未在亲和层析系统现场,导致未执行"1.3.11 产品管道排空冲洗"步骤。

影响评估:



PR#: 4346 Deviation No.:D-2020-0230

Record Status: Closed-Done

通过观察纯化区域上样管路中的视镜,可知信迪利单抗注射液M1b 3000L原液DS2006009 CF收获液未进入层析系统和层析柱。后重新执行"1.3.11产品管道排空冲洗",按照批记录中的规定打开了相应的阀门流路,进行管道排空,排空体积104.99L,符合批记录中"≥70L"的要求,管道排空冲洗之后开始上样,上样过程正常,未发生气泡陷阱报警,对实和层析Cycle1工艺无影响。

在重新执行"1.3.11产品管道排空冲洗"步骤前,已关闭罐底阀门XV-T0112-14,因此管道排空过程对信迪利单抗注射液M1b 3000L原

液DS2006009 CF收获液无影响。

综上,本偏差对DS2006009批次信迪利单抗注射液M1b3000L原液质量未造成影响。

生产/检测的影响评估 Production/Testing Impact Assessment:

N/A

其他影响评估描述 Other Impact Assessment Description:

N/A

初步影响评估附件 Initial Impact Assessment Attachment:

### 偏差分级 Deviation Classification

偏差严重性 Deviation Severity:

CF收获液未进入层析系统和层析柱,重新执行管道排空,排空体积为104.99L,符合批记录要求,管道排空冲洗之后开始上样,上样过程正常,未发生气泡陷阱报警,对亲和层析Cycle1工艺无影响。重新执行管道排空前已关闭罐底阀门,因此管道排空过程对CF收获液无影响。本偏差对DS2006009批次信迪利单抗注射液M1b 3000L原液质量未造成影响。

偏差发生率 Reoccurrence Probability of Deviation:

过去12个月内没有类似缺陷发生(搜索关键词:亲和层析、上样管道、排空),故不对偏差等级进行升级。

偏差分级 Deviation Classification: Minor

分级的理由 Reason for Classification:

08/03/2020 07:17 PM (GMT+8:00) added by 祯 吴 (PID-000094):

本偏差对DS2006009批次信迪利单抗注射液M1b 3000L原液质量未造成影响,且过去12个月内没有类似缺陷发生,故定义为次要偏差。

是否需要调查? Investigation Required?: No

主调查人 Lead investigator:

不需要调查的理由 Reason for not Investigation:

本偏差原因明确,且未对产品质量造成影响,故无需进一步调查。

### 调查总结&根本原因分析 Investigation & RCA

调查总结 Investigation Summary:

调查附件 Investigation Attachments:

根本原因分析 Root Cause Analysis:

未执行的"1.3.11 产品管道排空冲洗"步骤在《信迪利单抗注射液M1b 3000L原液纯化批生产记录》(BPR100322)第21页上,操作人员(05030045和05030032)在执行"1.3.10 亲和层析Cycle1的500L配液袋安装"时,将批记录第20页、21页拿至一次性混合器旁进行确认操作,未及时归还至亲和层析系统处的整份批记录中,也未与后续操作人员(20002046和20000387)进行沟通,因此操作人员(20002046和20000387)在执行批记录第22页"1.3.12 亲和层析Cycle1"步骤时由于批记录第21页未在亲和层析系统现场,导致未执行"1.3.11 产品管道排空冲洗"步骤。

根本原因分析附件 Root Cause Analysis Attachment:



PR#: 4346 Deviation No.:D-2020-0230

Record Status: Closed-Done

原因描述 Cause Description:

操作人员未及时归还拆分的批记录,并且未与后续操作人员进行沟通。

原因分类 Cause Category 原因子分类 Cause Sub-Category 原因归属部门 Cause Department

Human Communication M1b DS1

缺陷描述 Defect Description:

2020.08.01 15:42在除病毒前纯化间(26C15)进行批次DS2006009信迪利单抗注射液M1b 3000L原液纯化 AC1上样时,现场人员(05030032)发现未执行批记录中"1.3.11产品管道排空冲洗"步骤,与《信迪利单抗注射液M1b 3000L原液纯化批生产记录》(BPR100322)中规定亲和层析上样前上样管道应排空冲洗不符,故发起偏差。

缺陷类型分类 Defect Category 缺陷类型子分类 Defect Sub-Category

Others Human execution error

缺陷描述 Defect Description:

2020.08.01 15:42在除病毒前纯化间(26C15)进行批次DS2006009信迪利单抗注射液M1b 3000L原液纯化 AC1上样时,现场人员(05030032)发现未执行批记录中"1.3.11产品管道排空冲洗"步骤,与《信迪利单抗注射液M1b 3000L原液纯化批生产记录》(BPR100322)中规定亲和层析上样前上样管道应排空冲洗不符,故发起偏差。

缺陷类型分类 Defect Category 缺陷类型子分类 Defect Sub-Category

Production/Process Operation

是否是重复偏差 Repeat Deviation?: No

判定重复偏差的原因 Justification for Repeat Deviation:

过去12个月内没有类似缺陷发生(搜索关键词:亲和层析、上样管道、排空),故不是重复偏差。

重复偏差的原因描述 Reason of Repeat Deviation Description:

N/A

相关的重复偏差 Repeat Deviation Records

PR# deviation# 简短描述 Short Description Record Status

### 最终影响/风险评估 Final Impact/Risk Assessment

对产品质量的影响 Impact on Product Quality:

对其他批次的影响 Impact on Other Batches:

对系统/设备的影响 Impact on System/Equipment:

对验证状态的影响 Impact on Validation State:

对产品注册的影响 Impact on Product Registration:

对法规符合性的影响 Impact on Regulation Compliance:



PR#: 4346 Deviation No.:D-2020-0230

Record Status: Closed-Done

对稳定性的影响 Impact on Stability:

对其他方面的影响 Impact on Other Aspects:

受影响的部门 Impact Departments:

影响/风险评估附件 Impact/Risk Assessment Attachment:

## 受影响的产品信息 Impacted Product Information

产品最终处置建议 Product Disposition Proposal:

产品名称 Product Name: 信迪利单抗注射液M1b 3000L原液

产品代码 Product Code

DS30-308

产品批号 Batch No.:

DS2006009

数量 Quantity

3000L

处理决定 Disposition

### 受影响的物料信息 Impacted Material Information

物料名称 Material Name:

### 受影响的溶液信息 Impacted Media/Buffer Information

溶液名称 Media/Buffer Name:

## 受影响的设备信息 Impacted Equipment Information

设备名称 Equipment Name: 层析系统 设备代码 Equipment Code MFG-M1b2-004

#### 偏差处理措施 Deviation Action Items

PR#: 4364

责任人 Assigned To: 方, 银川(PID-000082)部门 Department:M1b DS1截止日期 Date Due: 2020.08.04完成日期 Completed Date: 2020.08.042020.08.04确认人 Verified By: 吴, 祯(PID-000094)确认日期 Verified On: 2020.08.04



PR#: 4346 Deviation No.:D-2020-0230

Record Status: Closed-Done

行动项详细描述 Action Description:

对M1b纯化一线人员进行培训,强调在执行批生产记录中的工艺操作时,应当确认页码是连续的。当操作需要将完整的一个工

序批记录拆分时,应当和该工序其他人员做好沟通,并及时归还拆分的记录。

### 纠正信息 Correction Information

PR#:

责任人 Assigned To: 部门 Department:

截止日期 Date Due: 完成日期 Completed Date:

确认人 Verified By: 确认日期 Verified On:

行动项详细描述 Action Description:

## 纠正与预防措施 CAPA

PR#:

责任人 Assigned To: 部门 Department:

截止日期 Date Due:

行动项详细描述 Action Description:

## 附件 File Attachments

## 关联记录 Reference Records

PR# **Record Type** 简短描述 Short Description **Record Status** 

### 相关子记录 Related children

PR# **Record Type** 简短描述 Short Description **Record Status** 4364 **Deviation Action Items** 对M1b纯化一线人员进行培训 Train the Closed-Done

personnel of M1b purification line 1



PR#: Deviation No.:D-2020-0230 4346

Record Status: Closed-Done			
Initial Approval			
QA Initial Review			
Area QA Initial Reviewed By:	赵, 琰	Area QA Initial Reviewed On:	2020.08.03 16:27
Classify Completed By:	吴, 祯	Classify Completed On:	2020.08.03 19:31
<b>Department Initial Review</b>			
Department Leader 1 Reviewed By:	康, 云	Department Leader 1 Reviewed On:	2020.08.03 22:15
Department Leader 2 Reviewed By:		Department Leader 2 Reviewed On:	
Department Leader 3 Reviewed By:		Department Leader 3 Reviewed On:	
Department Leader 4 Reviewed By:		Department Leader 4 Reviewed On:	
Department Leader 5 Reviewed By:		Department Leader 5 Reviewed On:	
Area QA Leader Reviewed By:	代, 圆圆	Area QA Leader Reviewed On:	2020.08.03 20:07
Quality Initial Approval			
Quality Approver 1 Approved By:	周, 峥	Quality Approver 1 Approved On:	2020.08.04 08:31
Quality Approver 2 Approved By:		Quality Approver 2 Approved On:	
Quality Approver 3 Approved By:		Quality Approver 3 Approved On:	
Final Approval			
QA Final Review			
QA Final Review			
QA Final Reviewed By:		QA Final Reviewed On:	
		QA Final Reviewed On:	
QA Final Reviewed By:		QA Final Reviewed On:  QA Representative Reviewed On:	
QA Final Reviewed By:  Investigator Final Review			
QA Final Reviewed By:  Investigator Final Review  QA Representative Reviewed By:		QA Representative Reviewed On:	
QA Final Reviewed By:  Investigator Final Review  QA Representative Reviewed By: Investigator 1 Reviewed By:		QA Representative Reviewed On: Investigator 1 Reviewed On:	
QA Final Reviewed By:  Investigator Final Review  QA Representative Reviewed By: Investigator 1 Reviewed By: Investigator 2 Reviewed By:		QA Representative Reviewed On: Investigator 1 Reviewed On: Investigator 2 Reviewed On:	
QA Final Reviewed By:  Investigator Final Review  QA Representative Reviewed By: Investigator 1 Reviewed By: Investigator 2 Reviewed By: Investigator 3 Reviewed By:		QA Representative Reviewed On: Investigator 1 Reviewed On: Investigator 2 Reviewed On: Investigator 3 Reviewed On:	
QA Final Reviewed By:  Investigator Final Review  QA Representative Reviewed By: Investigator 1 Reviewed By: Investigator 2 Reviewed By: Investigator 3 Reviewed By: Investigator 4 Reviewed By:		QA Representative Reviewed On: Investigator 1 Reviewed On: Investigator 2 Reviewed On: Investigator 3 Reviewed On: Investigator 4 Reviewed On:	
QA Final Reviewed By:  Investigator Final Review  QA Representative Reviewed By: Investigator 1 Reviewed By: Investigator 2 Reviewed By: Investigator 3 Reviewed By: Investigator 4 Reviewed By: Investigator 5 Reviewed By:		QA Representative Reviewed On: Investigator 1 Reviewed On: Investigator 2 Reviewed On: Investigator 3 Reviewed On: Investigator 4 Reviewed On: Investigator 5 Reviewed On:	
QA Final Reviewed By:  Investigator Final Review  QA Representative Reviewed By: Investigator 1 Reviewed By: Investigator 2 Reviewed By: Investigator 3 Reviewed By: Investigator 4 Reviewed By: Investigator 5 Reviewed By: Investigator 6 Reviewed By:		QA Representative Reviewed On: Investigator 1 Reviewed On: Investigator 2 Reviewed On: Investigator 3 Reviewed On: Investigator 4 Reviewed On: Investigator 5 Reviewed On: Investigator 6 Reviewed On:	
QA Final Reviewed By:  Investigator Final Review  QA Representative Reviewed By: Investigator 1 Reviewed By: Investigator 2 Reviewed By: Investigator 3 Reviewed By: Investigator 4 Reviewed By: Investigator 5 Reviewed By: Investigator 6 Reviewed By: Investigator 7 Reviewed By:		QA Representative Reviewed On: Investigator 1 Reviewed On: Investigator 2 Reviewed On: Investigator 3 Reviewed On: Investigator 4 Reviewed On: Investigator 5 Reviewed On: Investigator 6 Reviewed On: Investigator 7 Reviewed On:	
QA Final Reviewed By:  Investigator Final Review  QA Representative Reviewed By: Investigator 1 Reviewed By: Investigator 2 Reviewed By: Investigator 3 Reviewed By: Investigator 4 Reviewed By: Investigator 5 Reviewed By: Investigator 6 Reviewed By: Investigator 7 Reviewed By: Investigator 7 Reviewed By: Investigator 8 Reviewed By:	y:	QA Representative Reviewed On: Investigator 1 Reviewed On: Investigator 2 Reviewed On: Investigator 3 Reviewed On: Investigator 4 Reviewed On: Investigator 5 Reviewed On: Investigator 6 Reviewed On: Investigator 7 Reviewed On:	n:
QA Final Reviewed By:  Investigator Final Review  QA Representative Reviewed By: Investigator 1 Reviewed By: Investigator 2 Reviewed By: Investigator 3 Reviewed By: Investigator 4 Reviewed By: Investigator 5 Reviewed By: Investigator 6 Reviewed By: Investigator 7 Reviewed By: Investigator 8 Reviewed By: Investigator 8 Reviewed By: Investigator 8 Reviewed By: Investigator 8 Reviewed By:		QA Representative Reviewed On: Investigator 1 Reviewed On: Investigator 2 Reviewed On: Investigator 3 Reviewed On: Investigator 4 Reviewed On: Investigator 5 Reviewed On: Investigator 6 Reviewed On: Investigator 7 Reviewed On: Investigator 8 Reviewed On:	
QA Final Reviewed By:  Investigator Final Review  QA Representative Reviewed By: Investigator 1 Reviewed By: Investigator 2 Reviewed By: Investigator 3 Reviewed By: Investigator 4 Reviewed By: Investigator 5 Reviewed By: Investigator 6 Reviewed By: Investigator 7 Reviewed By: Investigator 8 Reviewed By: Investigator 8 Reviewed By: Investigator 8 Reviewed By: Department Final Approval  Department Leader 1 Final Approved By:	y:	QA Representative Reviewed On: Investigator 1 Reviewed On: Investigator 2 Reviewed On: Investigator 3 Reviewed On: Investigator 4 Reviewed On: Investigator 5 Reviewed On: Investigator 6 Reviewed On: Investigator 7 Reviewed On: Investigator 8 Reviewed On: Investigator 8 Reviewed On:	n:
QA Final Reviewed By:  Investigator Final Review  QA Representative Reviewed By: Investigator 1 Reviewed By: Investigator 2 Reviewed By: Investigator 3 Reviewed By: Investigator 4 Reviewed By: Investigator 5 Reviewed By: Investigator 6 Reviewed By: Investigator 7 Reviewed By: Investigator 7 Reviewed By: Investigator 8 Reviewed By: Investigator 8 Reviewed By: Department Final Approval  Department Leader 1 Final Approved By: Department Leader 2 Final Approved By:	y: y:	QA Representative Reviewed On: Investigator 1 Reviewed On: Investigator 2 Reviewed On: Investigator 3 Reviewed On: Investigator 4 Reviewed On: Investigator 5 Reviewed On: Investigator 6 Reviewed On: Investigator 7 Reviewed On: Investigator 8 Reviewed On: Investigator 8 Reviewed On: Investigator 8 Reviewed On: Investigator 8 Reviewed On:	n: n:
QA Final Reviewed By:  Investigator Final Review  QA Representative Reviewed By: Investigator 1 Reviewed By: Investigator 2 Reviewed By: Investigator 3 Reviewed By: Investigator 4 Reviewed By: Investigator 5 Reviewed By: Investigator 6 Reviewed By: Investigator 7 Reviewed By: Investigator 7 Reviewed By: Investigator 8 Reviewed By: Investigator 8 Reviewed By: Department Final Approval  Department Leader 1 Final Approved By Department Leader 2 Final Approved By Department Leader 3 Final Approved By	y: y: y:	QA Representative Reviewed On: Investigator 1 Reviewed On: Investigator 2 Reviewed On: Investigator 3 Reviewed On: Investigator 4 Reviewed On: Investigator 5 Reviewed On: Investigator 6 Reviewed On: Investigator 7 Reviewed On: Investigator 8 Reviewed On: Investigator 8 Reviewed On: Investigator 8 Reviewed On: Investigator 8 Reviewed On: Department Leader 1 Final Approved On: Department Leader 2 Final Approved On: Department Leader 3 Final Approved On:	n: n: n:

## **Quality Final Approval**

Quality Approver 1 Final Approved By: Quality Approver 1 Final Approved On: Quality Approver 2 Final Approved By: Quality Approver 2 Final Approved On:



PR#: 4346 Deviation No.:D-2020-0230

Record Status: Closed-Done

Quality Approver 3 Final Approved By: Quality Approver 3 Final Approved On:

**Product Final Disposition** 

Disposition Proposed By:

Proposal Reviewed By:

Disposition Proposed On:

Proposal Reviewed On:

Product Disposition Approved By: Product Disposition Approved On: